STAAR Surgical up 5% in New York as China rebound is in focus after Alcon deal
STAAR Surgical shares rose 5.5% to $29.81 in New York, outpacing other eye-care stocks after a strong first-quarter rebound in China. The company ended its takeover talks with Alcon in January after shareholders rejected a $30.75 per share offer. No new company news was released Thursday. China accounted for 51% of STAAR's net sales last quarter.